Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation

Transplantation

Volumn 87, Issue 1, 2009, Pages 125-132

  Pascual, Julio ^a   Pirsch, John D ^a   Odorico, Jon S ^a   Torrealba, José R ^a   Djamali, Arjang ^a   Becker, Yolanda T ^a   Voss, Barbara ^a   Leverson, Glen E ^a   Knechtle, Stuart J ^a   Sollinger, Hans W ^a   Samaniego Picota, Milagros D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Anti CD25 monoclonal antibody; B cell; Campath 1H; Induction therapy; Kidney transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BASILIXIMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; ACUTE DISEASE; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MORTALITY; NEOPLASM; SURVIVAL RATE;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; NEOPLASMS; PANCREAS TRANSPLANTATION; SURVIVAL RATE; TACROLIMUS;

EID: 58949100152     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818c6db0     Document Type: Article

References (26)

1. Rayhill SC, D'Alessandro AM, Odorico JS, et al. Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: Is there a difference in survival? Ann Surg 2000; 231: 417.
2. Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg 1998; 228: 284.
3. Di Carlo A, Odorico JS, Leverson GE, et al. Long-term outcomes in simultaneous pancreas-kidney transplantation: Lessons relearned. Clin Transpl 2003: 215.
4. Fernandez LA, Di Carlo A, Odorico JS, et al. Simultaneous pancreas-kidney transplantation from donation after cardiac death: Successful long-term outcomes. Ann Surg 2005; 242: 716.
5. Salvalaggio PR, Schnitzler MA, Abbott KC, et al. Patient and graft survival implications of simultaneous pancreas kidney transplantation from old donors. Am J Transplant 2007; 7: 1561.
6. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
7. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - Long-term results. Am J Transplant 2005; 5: 2539.
8. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - Long-term results. Am J Transplant 2006; 6: 331.
9. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
10. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - An addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
11. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
12. Drachenberg CB, Papadimitriou JC, Klassen DK, et al. Evaluation of pancreas transplant needle biopsy: Reproducibility and revision of his-tologic grading system. Transplantation 1997; 63: 1579.
13. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.
14. Andreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantationin the United States, 1996-2005. Am J Transplant 2007; 7: 1359.
15. Knechtle SJ, Pirsch JD, Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
16. Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - Efficacy and safety at five years. Am J Transpl 2005; 5: 1347.
17. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
18. Morris PJ, NK Russell. Alemtuzumab (Campath1H). A systematic review in organ transplantation. Transplantation 2006; 81: 1361.
19. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, myco-phenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
20. Huang E, Cho YW, Hayashi R, et al. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.
21. Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitor-and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005; 79: 1184.
22. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
23. Kirk AD, Hale DA, Swanson SJ,et al. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006; 6(5 Pt 1): 1084.
24. Coles AJ, Cox A, Le Page E. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98.
25. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous alemtu-zumab induction therapyinhighly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144.
26. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387.